Ovarian Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are able to understand and willing to sign a consent form agreeing to take part in the trial
• People who are at least 18 years old at the time of signing the consent form
• People who have been diagnosed with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, confirmed through laboratory testing of tissue samples
• People whose cancer has shown a specific pattern of resistance to platinum-based chemotherapy — either: (a) after first-line platinum treatment only, where the cancer responded but then came back between 3 and 6 months after the last platinum dose; or (b) after two or more lines of platinum treatment, where the cancer came back within 6 months of the last platinum dose (after at least two cycles)
• People whose cancer got worse during or after their most recent treatment, or who were unable to tolerate that treatment
• People who have received 2 to 3 lines of prior cancer treatment overall, with the cancer returning within 6 months (but at least 3 months) after the last platinum-based treatment
• People who have at least one area of cancer that can be measured on a scan, according to standard criteria (RECIST 1.1), that has not been treated with local therapies such as radiation — or if it was, there must be evidence the cancer has grown back in that area
• People with an expected survival of 6 months or more
• People with a general health score (called an ECOG score) of 0 or 1, meaning they are fully active or restricted in strenuous activity but able to carry out light work
• People with adequate organ and bone marrow function, confirmed by blood tests taken within 7 days before joining the trial
• People who are willing to provide either stored or freshly collected tumour tissue samples (confirm with trial site regarding exceptions if sample collection would be considered risky)
• People who are willing and able to follow all trial procedures and attend follow-up appointments

Who may not be able to join:

• People whose cancer never responded to first-line platinum chemotherapy at all, or whose cancer progressed within 3 months of the last platinum dose
• People with active cancer spread to the brain or the lining around the brain — though people with stable, symptom-free brain tumours that have not required steroids or anti-seizure medications for at least 2 weeks, confirmed by recent imaging, may still be considered (confirm with trial site)
• People who have taken part in another clinical trial involving an experimental drug within the 28 days before joining
• People who have received other cancer treatments or anti-cancer drugs within 28 days (or within 5 half-lives of the drug, whichever is shorter, but at least 14 days) before joining; or who have taken Chinese herbal medicines with known anti-cancer properties within 14 days before joining
• People who have received local palliative treatment (such as targeted radiation to a specific area) within 14 days before joining
• People who have had major surgery (such as abdominal or chest surgery) within 28 days before joining, or who are expected to need major surgery during the trial — minor procedures such as needle biopsies or port insertions are generally not included in this rule
• People with significant bowel or gastrointestinal problems, including: a bowel obstruction within the past 3 months (unless fully resolved by surgery); a gastrointestinal perforation, stomach opening procedure, or abdominal abscess within the past 3 months; severe gastrointestinal bleeding within the past 3 months; or any gastrointestinal bleeding within the past month (some exceptions may apply — confirm with trial site); people who have had a gastrointestinal stent placed that is still in place at screening are not eligible
• People with uncontrolled, recurring build-up of fluid in the chest, around the heart, or in the abdomen, or with significant unintentional weight loss
• People who have had another cancer diagnosis within the past 5 years, with the exception of certain early-stage or highly treatable skin cancers, non-invasive bladder cancer, or in-situ cancers of the prostate, cervix, or breast
• People with a history of lung inflammation (interstitial lung disease) that has required steroid treatment, or where such a condition cannot be ruled out on screening scans
• People with certain uncontrolled ongoing health conditions, including:
  • Active hepatitis B or C infection (people with hepatitis B or C who meet specific low viral load criteria may still be considered — confirm with trial site)
  • HIV infection
  • Active tuberculosis
  • Active syphilis
  • An active or uncontrolled infection requiring antibiotics or antifungal treatment within 2 weeks before joining
  • Very high blood pressure that cannot be controlled, severe heart failure, persistent low potassium levels, long QT syndrome, or moderate to severe high blood pressure in the lungs
  • Serious heart rhythm problems, including a history of certain dangerous irregular heartbeats or significant heart conduction problems
  • Unstable chest pain (angina) or a heart attack within the past 6 months
  • A newly diagnosed blood clot condition within the past 6 months (people with stable, managed blood clots such as those in leg veins or associated with infusion ports may still be considered — confirm with trial site)
• People still experiencing side effects from previous cancer treatment that have not improved to a mild level (grade 1 or lower on a standard scale) — though some stable, ongoing grade 2 side effects such as nerve damage, hair loss, fatigue, or hormone-related effects from prior immunotherapy may be acceptable (confirm with trial site)
• People who have previously had a bone marrow or organ transplant from another person
• People with a history of allergic reactions to antibody-based medicines
• People with other conditions the trial doctors believe could affect their safety or ability to follow the trial, including certain mental health conditions, alcohol dependence, or drug misuse

Important: Always verify eligibility with the trial site directly before applying.